UY27796A1 - Formulaciones farmacéuticas - Google Patents

Formulaciones farmacéuticas

Info

Publication number
UY27796A1
UY27796A1 UY27796A UY27796A UY27796A1 UY 27796 A1 UY27796 A1 UY 27796A1 UY 27796 A UY27796 A UY 27796A UY 27796 A UY27796 A UY 27796A UY 27796 A1 UY27796 A1 UY 27796A1
Authority
UY
Uruguay
Prior art keywords
desmopressin
formulated
way
pharmaceutical formulations
pne
Prior art date
Application number
UY27796A
Other languages
English (en)
Inventor
Anders Nilsson
Thomas Senderovitz
Hans Lindner
Jorgen Wittendorff
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9936186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of UY27796A1 publication Critical patent/UY27796A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es posible obtener una buena biodisponibilidad de desmopresina por medio de una forma de dosificación farmacéutica orodispersable. Las formas de dosificación preferidas comprenden desmopresina y una red de matriz abierta que es un material vehículo inerte soluble en agua o dispersable en agua. La desmopresina formulada de este modo es útil para posponer la evacuación, o para tratar o prevenir la incontinencia, la enuresis nocturna primaria (PNE), la nocturia o la diabetes insípida central. Pueden también formularse de este modo péptidos distintos de la desmopresina.
UY27796A 2002-05-07 2003-05-07 Formulaciones farmacéuticas UY27796A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210397.6A GB0210397D0 (en) 2002-05-07 2002-05-07 Pharmaceutical formulations
PCT/IB2002/004036 WO2003094885A1 (en) 2002-05-07 2002-09-20 Sublingual pharmaceutical formulation of desmopressin

Publications (1)

Publication Number Publication Date
UY27796A1 true UY27796A1 (es) 2003-11-28

Family

ID=9936186

Family Applications (2)

Application Number Title Priority Date Filing Date
UY27683A UY27683A1 (es) 2002-05-07 2003-02-26 Formulaciones farmacéuticas
UY27796A UY27796A1 (es) 2002-05-07 2003-05-07 Formulaciones farmacéuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY27683A UY27683A1 (es) 2002-05-07 2003-02-26 Formulaciones farmacéuticas

Country Status (22)

Country Link
US (14) US7560429B2 (es)
EP (1) EP1501534B1 (es)
KR (1) KR100632455B1 (es)
CN (2) CN1319592C (es)
AR (3) AR039092A1 (es)
AT (1) ATE333886T1 (es)
AU (2) AU2002337419A1 (es)
DK (1) DK1501534T5 (es)
ES (1) ES2266820T4 (es)
GB (1) GB0210397D0 (es)
HK (1) HK1074393A1 (es)
IL (1) IL164519A (es)
MX (1) MXPA04010926A (es)
MY (1) MY131153A (es)
PL (1) PL208482B1 (es)
RU (1) RU2292903C2 (es)
SI (1) SI1501534T1 (es)
TW (1) TWI315202B (es)
UA (1) UA85664C2 (es)
UY (2) UY27683A1 (es)
WO (2) WO2003094885A1 (es)
ZA (1) ZA200408596B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
US20040236673A1 (en) * 2000-10-17 2004-11-25 Eder Jeff Scott Collaborative risk transfer system
US20080027769A1 (en) 2002-09-09 2008-01-31 Jeff Scott Eder Knowledge based performance management system
US20080256069A1 (en) * 2002-09-09 2008-10-16 Jeffrey Scott Eder Complete Context(tm) Query System
US20110040631A1 (en) * 2005-07-09 2011-02-17 Jeffrey Scott Eder Personalized commerce system
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
EP2322197A2 (en) * 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
DE60305043T2 (de) 2003-11-13 2006-11-30 Ferring B.V. Blisterverpackung und feste Dosierungsform enthaltend Desmopressin
GB0406048D0 (en) * 2004-03-18 2004-04-21 Ardana Bioscience Ltd Drug formulations
US20090043637A1 (en) * 2004-06-01 2009-02-12 Eder Jeffrey Scott Extended value and risk management system
US7972621B2 (en) 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US8713025B2 (en) 2005-03-31 2014-04-29 Square Halt Solutions, Limited Liability Company Complete context search system
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US8498915B2 (en) 2006-04-02 2013-07-30 Asset Reliance, Inc. Data processing framework for financial services
US7788434B2 (en) * 2006-12-15 2010-08-31 Microchip Technology Incorporated Interrupt controller handling interrupts with and without coalescing
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
CA2988753A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
CN101372504B (zh) * 2007-08-22 2011-05-18 深圳翰宇药业股份有限公司 一种纯化去氨加压素的方法
US20100121307A1 (en) * 2007-08-24 2010-05-13 Microfabrica Inc. Microneedles, Microneedle Arrays, Methods for Making, and Transdermal and/or Intradermal Applications
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
ES2462465T5 (es) * 2008-05-21 2018-02-28 Ferring B.V. Desmopresina bucodispersable para aumentar el periodo inicial del sueño no alterado por nocturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100160214A1 (en) * 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
AU2015261630B2 (en) * 2008-12-22 2017-09-14 Acerus Pharmaceuticals USA, LLC Intranasal desmopressin administration
JP5731396B2 (ja) 2008-12-22 2015-06-10 アラガン，インコーポレイティド 鼻腔内デスモプレシン投与
MX343193B (es) * 2009-06-18 2016-10-26 Allergan Inc Administracion segura de desmopresina.
TR201902233T4 (tr) * 2009-10-30 2019-03-21 Ix Biopharma Ltd Hızlı çözünen katı dozaj formu.
GB0920041D0 (en) * 2009-11-16 2009-12-30 Univ Aston Tablet
AU2011234637B2 (en) 2010-03-29 2013-08-29 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AR083361A1 (es) * 2010-10-08 2013-02-21 Scherer Technologies Inc R P Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
EP2755632A1 (en) 2011-09-16 2014-07-23 Ferring BV A fast dissolving pharmaceutical composition
EP3275466A1 (en) * 2012-07-12 2018-01-31 Ferring B.V. Diclofenac formulations
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
CA2908232A1 (en) * 2013-03-26 2014-10-02 Optinose As Nasal administration of fluticasone and carbon dioxide
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
AU2014293140A1 (en) 2013-07-23 2016-03-03 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
KR20240015735A (ko) * 2013-07-23 2024-02-05 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
WO2015063602A1 (en) 2013-10-29 2015-05-07 Ferring B.V. Desmopressin and blood glucose
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
ES2923438T3 (es) 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
ITUB20156821A1 (it) * 2015-12-09 2017-06-09 Altergon Sa CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE
MY195591A (en) 2017-01-11 2023-02-02 Ferring Bv A Fast Disintegrating Pharmaceutical Composition
CN108113974A (zh) * 2018-02-05 2018-06-05 上海祺宇生物科技有限公司 一种多孔性空心胶囊的制备方法以及由此制备的胶囊
US10940088B1 (en) 2020-01-09 2021-03-09 King Saud University Method of preparing low dose pharmaceutical formulations
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4387624A1 (en) * 2021-08-19 2024-06-26 Mind Medicine, Inc. Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4285858A (en) * 1979-10-30 1981-08-25 Mt. Sinai School Of Medicine Of The City University Of N.Y. Vasopressin analogs
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4263283A (en) * 1980-05-16 1981-04-21 Ferring Pharmaceuticals, Inc. Method for prophylaxis and/or treatment of sickle cell disease
US4371316A (en) * 1981-03-23 1983-02-01 Michael Ivic Control for a bilge pump
GB2111423B (en) 1981-12-02 1985-06-26 Wyeth John & Brother Ltd Making quick-dissolving pills
EP0084705B1 (en) 1981-12-11 1987-01-14 JOHN WYETH & BROTHER LIMITED Process for preparing solid shaped articles
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
SE8306367L (sv) * 1983-11-18 1985-05-19 Ferring Ab Antidiuretiskt verkande farmaceutiskt preparat
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4623283A (en) * 1984-06-13 1986-11-18 Mobil Oil Corporation Method for controlling water influx into underground cavities
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4878892A (en) * 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4878592A (en) * 1988-06-28 1989-11-07 Zarn, Inc. Apparatus for segregated refuse collection
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
ATE108326T1 (de) * 1989-01-30 1994-07-15 Corint Ltd Wässerige desmopressin-cmc enthaltende arzneizubereitung.
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
TW279133B (es) 1990-12-13 1996-06-21 Elan Med Tech
SE9101022D0 (sv) 1991-01-09 1991-04-08 Paal Svedman Medicinsk suganordning
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
AU666509B2 (en) * 1991-12-24 1996-02-15 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
US5298256A (en) * 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
CA2090738C (en) * 1993-02-24 1996-05-21 Hema-Quebec Use of paf
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
SE501677C2 (sv) 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
DE69424940T2 (de) * 1993-06-29 2000-12-28 Ferring B.V., Hoofdorp Synthese zyklischer peptide
US5985835A (en) * 1993-12-23 1999-11-16 Ferring B.V. Desmopressin for nocturia, incontinence and enuresis
PT708657E (pt) * 1993-06-29 2001-11-30 Ferring Bv Composicoes para administracao nasal de desmopressina
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5674850A (en) * 1993-12-23 1997-10-07 Ferring Ab High purity desmopressin produced in large single batches
US5500413A (en) * 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5707648A (en) * 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery
AU1677095A (en) * 1994-01-11 1995-08-01 Alkermes Controlled Therapeutics, Inc. Oral dosage form of desmopressin (ddavp)
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
SE9400918L (sv) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
US5611806A (en) 1994-05-23 1997-03-18 Samsung Electro-Mechanics Co., Ltd. Skin perforating device for transdermal medication
KR0134152B1 (ko) 1994-05-23 1998-04-14 이형도 의약품 투여용 피부흠집 형성장치
GB9410388D0 (en) 1994-05-24 1994-07-13 Erba Carlo Spa Method for the preparation of 9-amino camptothecin
US5495898A (en) * 1994-07-13 1996-03-05 Champion Road Machinery Limited Blade control system for motor graders
SE518619C2 (sv) * 1994-12-09 2002-10-29 Gs Dev Ab Komposition för reglerad frisättning innehållande monokaproin
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
AU5740496A (en) 1995-05-22 1996-12-11 General Hospital Corporation, The Micromechanical device and method for enhancing delivery of compounds through the skin
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
DE19602757A1 (de) 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5843016A (en) 1996-03-18 1998-12-01 Physion S.R.L. Electromotive drug administration for treatment of acute urinary outflow obstruction
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
ZA975326B (en) * 1996-06-18 1998-01-14 Alza Corp Device and method for enhancing transdermal flux of agents being delivered or sampled.
US5763398A (en) * 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
US5922680A (en) * 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
FR2758195B1 (fr) 1997-01-09 1999-02-26 Sgs Thomson Microelectronics Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele
US5985385A (en) 1997-05-23 1999-11-16 No Fire Technologies, Inc. Fire and heat protection wrap for conduits, cable trays, other electrical transmission lines and gas and oil pipelines
US5932745A (en) * 1997-07-30 1999-08-03 American Home Products Corporation Process for converting propargylic amine-N-oxides to enaminones
US6194407B1 (en) * 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6511974B1 (en) * 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US6248636B1 (en) * 1998-05-28 2001-06-19 Samsung Electronics Co., Ltd. Method for forming contact holes of semiconductor memory device
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
US6423346B1 (en) * 1998-08-25 2002-07-23 Basf Health & Nutrition A/S Fish gelatinous composition for use as an ingredient in tablets
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
GB9827292D0 (en) 1998-12-12 1999-02-03 Univ Strathclyde Freeze drying
US6406455B1 (en) 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
US6344451B1 (en) * 1999-02-04 2002-02-05 American Home Products Pyrrolobenzodiazepine carboxyamide vasopressin agonists
US6297234B1 (en) * 1999-02-04 2001-10-02 American Home Products Corporation Arylthiophene vasopressin agonists
US6620807B1 (en) * 1999-02-04 2003-09-16 Wyeth Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
US6235900B1 (en) * 1999-02-04 2001-05-22 American Home Products Corporation Tricyclic pyridine N-oxides vasopressin agonists
TWI271198B (en) * 1999-02-15 2007-01-21 Dainippon Sumitomo Pharma Co Tables disintegrating rapidly in the oral cavity
US6314317B1 (en) 1999-02-18 2001-11-06 Biovalve Technologies, Inc. Electroactive pore
AR014640A1 (es) * 1999-02-23 2001-03-28 Univ Nac Quilmes UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB2355454A (en) 1999-10-20 2001-04-25 Ferring Bv Antidiuretic agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
CA2396569C (en) * 2000-01-07 2010-03-23 Biovalve Technologies, Inc. Injection device
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
GB0015601D0 (en) * 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
HUP0302924A2 (en) * 2000-10-26 2003-12-29 Alza Corp Transdermal drug delivery devices having coated microprotrusions
WO2002051470A2 (en) 2000-11-30 2002-07-04 Biovalve Technologies, Inc. Injection systems
ES2574917T3 (es) * 2000-11-30 2016-06-23 Valeritas, Inc. Sistemas y procedimientos de suministro y medición de fluido
EP1345646A2 (en) 2000-12-14 2003-09-24 Georgia Tech Research Corporation Microneedle devices and production thereof
AU2002231207A1 (en) * 2000-12-21 2002-07-01 Biovalve Technologies, Inc. Microneedle array systems
NZ528148A (en) 2001-03-16 2006-02-24 Alza Corp Transdermal patch for administering fentanyl
EP1381608B1 (en) * 2001-04-12 2007-10-10 Wyeth Cyclohexylphenyl vasopressin agonists
US7022699B2 (en) * 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
CA2444455A1 (en) * 2001-04-12 2002-10-24 Amedeo Arturo Failli N-biphenylcarbonyl- and n-phenylpyridylcarbonyl substituted bi- and tricyclic azepines and diazepines as vasopressing agonists
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US6667277B2 (en) 2001-08-24 2003-12-23 National Starch And Chemical Investment Holding Corporation Water dispersible starch based physical form modification of agricultural agents
US7615234B2 (en) 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
CN1275936C (zh) 2001-09-13 2006-09-20 橘生药品工业株式会社 羟基去甲麻黄素衍生物的各种结晶体型
WO2003026804A1 (de) * 2001-09-21 2003-04-03 Ing. Erich Pfeiffer Gmbh Dosiervorrichtung mit einem medienspeicher sowie einer pumpvorrichtung
US6723077B2 (en) 2001-09-28 2004-04-20 Hewlett-Packard Development Company, L.P. Cutaneous administration system
US6893655B2 (en) 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
KR100632882B1 (ko) * 2001-11-16 2006-10-13 아스텔라스세이야쿠 가부시키가이샤 4, 4-디플루오로-1, 2, 3,4-테트라하이드로-5ｈ-1-벤즈아제핀 유도체 또는 그 염
NZ535861A (en) 2002-05-07 2006-11-30 Ferring Bv Desmopressin acetate in an orodispersible dosage form that disintegrates in the mouth within 10 seconds
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2003097080A1 (en) 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited A stable aqueous composition of a peptide
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
GB2421689B (en) 2002-08-05 2007-03-07 Caretek Medical Ltd Drug delivery system
AU2003275301A1 (en) * 2002-09-30 2004-04-23 Alza Corporation Drug delivery device having coated microprojections incorporating vasoconstrictors
ES2479042T3 (es) * 2002-10-09 2014-07-23 Toray Industries, Inc. Remedios o agentes preventivos de la incontinencia urinaria y derivados de morfinano que presentan un grupo heterocíclico que contiene nitrógeno
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
BR0316270B1 (pt) 2002-11-14 2014-10-29 Ube Industries Composição cosmética
DE10259934B3 (de) 2002-12-20 2004-10-14 H.C. Starck Gmbh Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
US20040155167A1 (en) * 2003-02-07 2004-08-12 Ergodontics System and method of mounting a display screen via a pendulum type mount
RU2326868C2 (ru) * 2003-04-28 2008-06-20 Астеллас Фарма Инк. Производное 4,4-дифтор-1,2,2,4-тетрагидро-5н-1-бензазепина или его соль
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DK1473029T3 (da) 2003-04-30 2005-04-18 Ferring Bv Farmaceutisk præparat som fast dosisform og fremgangsmåde til fremstilling deraf
US7094545B2 (en) * 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
AU2004255228A1 (en) 2003-06-30 2005-01-20 Alza Corporation Method for coating skin piercing microprojections
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
EP1500390B1 (en) 2003-07-25 2005-08-17 Ferring B.V. Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof
US6930932B2 (en) 2003-08-27 2005-08-16 Hewlett-Packard Development Company, L.P. Data signal reception latch control using clock aligned relative to strobe signal
AU2004285481A1 (en) * 2003-10-24 2005-05-12 Alza Corporation Apparatus and method for enhancing transdermal drug delivery
BRPI0415466A (pt) * 2003-10-24 2006-12-19 Alza Corp método e sistema de pré-tratamento para intensificar a distribuição transdérmica de fármacos
JP4682144B2 (ja) * 2003-10-31 2011-05-11 アルザ・コーポレーシヨン 微小突起列のための自己−作動性アプリケーター
EP2322197A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
DE60305043T2 (de) * 2003-11-13 2006-11-30 Ferring B.V. Blisterverpackung und feste Dosierungsform enthaltend Desmopressin
US7344725B2 (en) 2003-11-25 2008-03-18 Alcon, Inc. Use of inorganic nanoparticles to stabilize hydrogen peroxide solutions
US7018653B2 (en) * 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
EP1550439B1 (en) 2003-12-29 2006-03-08 Ferring B.V. Method for preparing a solid dosage form of desmopressin
CA2490601C (en) 2003-12-29 2006-05-02 Ferring B.V. Method for preparing solid dosage form of desmopressin
MXPA06007832A (es) * 2004-01-09 2007-01-26 Johnson & Johnson Metodo y sistema de suministro de agente transdermico asistido por frecuencia.
HUE028833T2 (en) * 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
US7097776B2 (en) 2004-10-22 2006-08-29 Hewlett-Packard Development Company, L.P. Method of fabricating microneedles
US20060093658A1 (en) * 2004-10-26 2006-05-04 Gayatri Sathyan Apparatus and method for transdermal delivery of desmopressin
US20080009801A1 (en) 2004-12-02 2008-01-10 Nickel Janice H Method for dispensing material into a drug delivery device
US7180274B2 (en) 2004-12-10 2007-02-20 Aimtron Technology Corp. Switching voltage regulator operating without a discontinuous mode
AU2006212021B2 (en) 2005-02-10 2010-09-30 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
US7856263B2 (en) 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239930A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
AR056980A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
SE0600482L (sv) 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
CA2988753A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
US20100160214A1 (en) * 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition

Also Published As

Publication number Publication date
US20170112895A1 (en) 2017-04-27
US7947654B2 (en) 2011-05-24
US8802624B2 (en) 2014-08-12
PL375497A1 (en) 2005-11-28
TWI315202B (en) 2009-10-01
EP1501534B1 (en) 2006-07-26
ES2266820T4 (es) 2014-12-30
GB0210397D0 (en) 2002-06-12
ZA200408596B (en) 2006-06-28
KR20050009999A (ko) 2005-01-26
US20120322734A1 (en) 2012-12-20
CN1981745A (zh) 2007-06-20
US8143225B2 (en) 2012-03-27
WO2004041153A2 (en) 2004-05-21
DK1501534T5 (da) 2014-12-15
US20160175246A1 (en) 2016-06-23
US7560429B2 (en) 2009-07-14
ES2266820T3 (es) 2007-03-01
AU2003299480A1 (en) 2004-06-07
AR107948A2 (es) 2018-07-04
WO2003094885A1 (en) 2003-11-20
MXPA04010926A (es) 2005-02-14
WO2004041153A3 (en) 2004-08-26
AR039092A1 (es) 2005-02-09
CN1649615A (zh) 2005-08-03
US20080274951A1 (en) 2008-11-06
IL164519A0 (en) 2005-12-18
RU2292903C2 (ru) 2007-02-10
US7405203B2 (en) 2008-07-29
AU2003299480A8 (en) 2004-06-07
PL208482B1 (pl) 2011-05-31
US20090318665A1 (en) 2009-12-24
US20120071538A1 (en) 2012-03-22
US9504647B2 (en) 2016-11-29
ATE333886T1 (de) 2006-08-15
US20050232997A1 (en) 2005-10-20
US20150150938A1 (en) 2015-06-04
UA85664C2 (ru) 2009-02-25
RU2004130435A (ru) 2005-08-10
US20180280469A1 (en) 2018-10-04
AR039794A1 (es) 2005-03-02
CN1319592C (zh) 2007-06-06
KR100632455B1 (ko) 2006-10-11
MY131153A (en) 2007-07-31
TW200400054A (en) 2004-01-01
US7799761B2 (en) 2010-09-21
US20040138098A1 (en) 2004-07-15
US20210161810A1 (en) 2021-06-03
US10307459B2 (en) 2019-06-04
IL164519A (en) 2009-09-22
AU2002337419A1 (en) 2003-11-11
HK1074393A1 (en) 2005-11-11
UY27683A1 (es) 2003-12-31
US20100056436A1 (en) 2010-03-04
US9919025B2 (en) 2018-03-20
SI1501534T1 (sl) 2006-12-31
US20090005432A1 (en) 2009-01-01
US20070265207A1 (en) 2007-11-15
US7579321B2 (en) 2009-08-25
EP1501534A2 (en) 2005-02-02
US9220747B2 (en) 2015-12-29
DK1501534T3 (da) 2006-11-20

Similar Documents

Publication Publication Date Title
UY27796A1 (es) Formulaciones farmacéuticas
AU2003274681A8 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
IL152294A0 (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR046510A1 (es) Composicion de un antagonista de vegf y un agente anti-proliferativo
ECSP083351A (es) Composiciones farmacéuticas
AR074528A1 (es) Dispositivos intravaginales con un soporte rigido, metodos para su fabricacion y sus usos
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
ATE381951T1 (de) Medizinischer ballon
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
BR0206473A (pt) Pelìcula comestìvel
AR034517A1 (es) Formulacion farmaceutica
CO5540373A2 (es) Composicion farmaceutica de liberacion sostenida
ATE339224T1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
CL2007003010A1 (es) Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03).
BG108870A (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
DE60140997D1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
PL376343A1 (en) Amended recombinant cells (arcs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants
MXPA01011249A (es) Metodo para la manufactura de dispositivos surtidores de mercurio para ser utilizados en lamparas fluorescentes.
UY29185A1 (es) Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
CL2004000884A1 (es) Composicion farmaceutica en forma de hidrogel que contiene un diester de acido carbonico, un alquilalcohol c2-c4, por lo menos una sustancia activa y una matriz de polimero; uso en el tratamiento de carencias esteroidales.
AR014082A1 (es) Concentrado oral de sertralina
CR8973A (es) Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua
DK1499278T3 (da) Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon
ITMI20000178A0 (it) Apparecchiatura e procedimento per alimentare in automatico una cucitrice della punta di una calza
EP1494633A4 (en) ADHESIVE N, O-CARBOXYMETHYLCHITOSAN DRUG DELIVERY DEVICES FOR WET TISSUES AND METHODS OF USE

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520

RDES Application refused

Effective date: 20180807